Replies to post #6806 on CytoSorbents Corporation (CTSO)

[Paulness]

100% of all start ups in the biotechnology business are up on future earnings ,and most aren't even selling product , Cytosorbents is a rare one ,that is selling product overseas while waiting on FDA approval, a very low Market cap, this will change very soon, and everyone will be surprised again and wished they didn't sell and had bought at these levels , institutions will be buying a lot here at these bargain basement prices.

[andy55q]

CytoSorbents has conducted two multicenter studies with a total of 150 patients for the indications of severe sepsis and septic shock in Europe in order to evaluate the safety and effectiveness of CytoSorb when used continuously up to 24 hours per daily treatment. The company works closely with renowned medical doctors in the field of sepsis research and intensive care. Publication of these studies are planned this year.

http://cytosorb-therapy.com/the-studies/multicentre-trials/

Numerous well-known German and international hospitals are currently performing monocentric scientific studies on the efficacy and clinical effects of the use of CytoSorb in a variety of hyper-inflammatory conditions (e.g. severe sepsis, septic shock, acute pancreatitis, trauma, and consequences of cardiopulmonary bypass in cardiac surgery). Several studies in other application areas such as burn injury or liver failure are in preparation. In total, more than 40 investigator studies are in process, with approximately 12 enrolling and the rest in various stages of planning.

http://cytosorb-therapy.com/the-studies/iit-single/